Quantel Medical announced that it has received approval from the FDA for the new A/B/S ultrasound platform: ABSolu.
The ABSolu includes a new 5 ring annular technology 20MHz B probe that increases the depth of field by 70%, offering high definition information of the vitreous, retinal wall, and orbit in a single scan. ABSolu also features standardized A Mode that complies with all the hardware and software requirements necessary for proper tissue characterization essential for tumor diagnosis as per the requirements of Prof. K. Ossoinig.
“ABSolu is our new ultrasound platform replacing our flagship ultrasound system Aviso. It is the achievement of years of work carried out by our R&D Department in collaboration with ultrasound specialists and we can say that once again, we are setting new standards in ophthalmic ultrasound imaging,” Jean-Marc Gendre, CEO of Quantel Medical, said in a company news release. “For ophthalmologists looking for excellence in ultrasound imaging, ABSolu is the ideal partner in their everyday practice.”
Motion sensors have been integrated in all B Mode and UBM probes allowing for an automatic and constant detection of the probe position and ultrasound beam direction (patented technology). A new signal processing for the linear 50 MHz UBM offers high image quality of the anterior chamber and lens. And a new full HD screen compliant with section 14 of the DICOM standard, a premiere in ophthalmic ultrasound.
Quantel Medical will showcase the new ABSolu Ultrasound Platform at the upcoming ASCRS Congress, to be held in San Diego May 3-07, in exhibit booth #631.